Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03099005 · ClinicalTrials.gov registry record · Phase 2

Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain

A Phase 2 study of Cannabis and Pain Syndrome, sponsored by University of California, San Diego.

Compiled by PlainTrial · August 8, 2026

Completed
Registry status: Phase 2
Development phase: 5
Enrollment target: 1
Study location

NCT03099005: Completed Phase 2 study of Cannabis and Pain Syndrome, sponsored by University of California, San Diego.

NCT03099005 is a Phase 2 study of Cannabis and Pain Syndrome that has completed, run by University of California, San Diego. The registered enrollment target is 5 participants, below the 111-participant average among 24 other Cannabis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03099005, a Phase 2 study of Cannabis and Pain Syndrome, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status: Phase 2
Development phase: 5 participants
Enrollment target: 1
Study location

Study Summary

Acute cannabis administration is reported to alleviate HIV neuropathic pain (HIV-NP), but there is limited knowledge about the effects of cannabis constituents (delta-9 tetrahydrocannabinol/THC and cannabidiol/CBD), the consequences of long-term cannabis use, and the impact of cannabis on endocannabinoid (EC) function in people living with HIV- NP. Our objective is to address these three fundamental gaps in our knowledge by: 1) examining the acute effects of various CBD/THC products on HIV-NP, 2) utilizing a mHealth text messaging protocol, Individual Monitoring of Pain and Cannabis Taken (IMPACT) to monitor daily real-world cannabis use and changes in pain; and 3) studying the relationship between cannabinoids, EC biomarkers, and chronic neuropathic pain

Primary Outcome

This is a scale from 0 to 10 indicating the self-reported level of pain. 0 is the minimum score, indicating no pain. 10 is the maximum score indicating highest level of pain.

Conditions Studied

Cannabis Pain Syndrome HIV Neuropathy

Interventions

DRUG Cannabis

Study Locations (1)

California

UC Center for Medicinal Cannabis Research, UC San Diego - San Diego

Trial Details

Field	Value
Enrollment Target	5 participants
Start Date	2018-07-01
Est. Completion	2022-12-31
Phase	Phase 2

University of California, San Diego

775 total trials

What the finished NCT03099005 record still lists

NCT03099005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 111-participant average among 24 other Cannabis trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Cannabis appearing as the primary indexed condition, and to 1 intervention - of which Cannabis is the first listed.

NCT03099005 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03099005 about?

NCT03099005 is a clinical study titled "Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain". Acute cannabis administration is reported to alleviate HIV neuropathic pain (HIV-NP), but there is limited knowledge about the effects of cannabis constituents (delta-9 tetrahydrocannabinol/THC and cannabidiol/CBD), the consequences of long-term cannabis use, and the impact of cannabis on endocannab...

What is the current status of trial NCT03099005?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-07-01. Estimated completion is 2022-12-31.

What conditions does trial NCT03099005 study?

This clinical trial studies the following conditions: Cannabis, Pain Syndrome, HIV Neuropathy.

What interventions are being tested in trial NCT03099005?

The interventions under investigation include: Cannabis (DRUG).

Who is sponsoring clinical trial NCT03099005?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03099005 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cannabis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03099005's enrollment target sits among peer trials

5 24th of 24 higher than 1 of 24 other Cannabis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cannabis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03099005, the US trial registry maintained by the National Library of Medicine. NCT03099005 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.